Financial Data and Key Metrics Changes - Revenue for Q4 2019 totaled $6.9 million, with full-year revenue of $28.9 million, reflecting a decline in recurring revenue by 7% primarily due to reduced service revenue [37][39] - System revenue for the full year increased to $2.1 million from $1.6 million, indicating growth in new robotic programs [37] - Gross margin for Q4 and full year 2019 were approximately 75% and 79% respectively, while operating expenses for the full year increased to $27.6 million from $26.1 million in 2018 [38][39] - The company ended 2019 with $30 million in cash and no debt, positioning itself for long-term growth [18][39] Business Line Data and Key Metrics Changes - Recurring revenue for the full year 2019 was $25.8 million, down from the previous year, primarily due to aging inactive accounts [37] - The company has established a new robotic program contributing to system revenue growth, although overall recurring revenue has declined [37] Market Data and Key Metrics Changes - The company has less than 1% market share in the cardiac ablation market, indicating significant room for growth [16] - Approximately 5% of recurring revenue comes from China, with a noted decline in cardiac ablation procedures during the early stages of the COVID-19 outbreak [44][45] Company Strategy and Development Direction - The company aims to transform endovascular surgery with robotics, focusing initially on cardiac ablation as a primary application [16] - Stereotaxis is investing in commercial infrastructure, including clinical field teams and training programs, to support robotic practices [19][21] - The Genesis Robotic system represents a significant advancement in technology, with FDA clearance received, and is expected to drive future sales [26][41] Management's Comments on Operating Environment and Future Outlook - Management anticipates robust double-digit revenue growth in 2020 driven by the commercialization of the Genesis system [41] - The company is cautiously optimistic about the impact of COVID-19, noting that most cardiac ablation procedures are not discretionary and can only be delayed [44][45] Other Important Information - The company has made significant progress in innovation and collaboration, including partnerships for mapping technologies and the development of a next-generation magnetic ablation catheter [30][33] - The OpenMapping software architecture is part of a broader strategy to create a competitive ecosystem around robotics [61] Q&A Session Summary Question: Sales funnel and demand for Genesis - Management confirmed two orders received, one from a new customer and one replacement, with a focus on ensuring the replacement cycle becomes real [48] Question: Osypka collaboration and regulatory pathway - The company is refining the catheter design and expects to conduct additional animal studies, with plans for initial clinical trials in 2020 [51][52] Question: Focus beyond cardiac applications - Management indicated that neurovascular applications are a high priority, alongside other interventional medicine areas [56] Question: Announcement of new system orders - The company aims to shift towards quarterly announcements rather than individual system orders, allowing hospitals to showcase their leadership [58] Question: OpenMapping API and strategic initiative - The OpenMapping API is part of a broader strategy to create an open ecosystem, with several physicians already using the integrated systems [60][62] Question: Upgrade plans for existing systems - Existing customers are expected to upgrade to the Genesis system as they approach standard lab replacements, with a focus on maintaining customer engagement [71] Question: Sales strategy for existing and new customers - The company is building capabilities for both existing customer upgrades and new system sales, with a clinical team already in place to address customer needs [74]

Stereotaxis, Inc. (NYSE:STXS) Q3 2019 Earnings Conference Call November 14, 2019 9:00 AM ET Company Participants David Fischel - CEO & Chairman Kimberly Peery - CFO Conference Call Participants Joshua Jennings - Cowen and Company Guy Judkowski - Logan Capital Management John Morganelli - Private Investor Operator Good morning. Thank you for joining us for the Stereotaxis Third Quarter 2019 Earnings Conference Call. Certain statements during the conference call and the question-and-answer period to follow m ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 (Exact name of registrant as specified in its charter) Delaware 94-3120386 (State of Incorporation) 4320 Forest Park Avenue Suite 100 St. Louis, Missouri 63108 (Address of principal executive offices) (Zip Code) identification no.) Registrant's telephone number, including area code: (314 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36159 STEREOTAXIS, INC. (Exact name of registrant as specified in its charter) (State of Incorporation) Delaware 94-3120386 (I.R.S. employ ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Commission File Number: 001-36159 WASHINGTON, D.C. 20549 STEREOTAXIS, INC. FORM 10-Q (Exact name of registrant as specified in its charter) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Indicate by check mark whether the registrant has submitte ...

Stereotaxis, Inc. (NYSE:STXS) Q1 2019 Earnings Conference Call May 9, 2019 9:00 AM ET Company Participants David Fischel - CEO & Chairman Martin Stammer - CFO Conference Call Participants Joshua Jennings - Cowen and Company Operator Good morning. Thank you for joining us for Stereotaxis First Quarter 2019 Earnings Conference Call. Certain statements during the conference call and question-and-answer period to follow may relate to future events, expectations and, as such, constitute forward-looking statement ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (MARK ONE) [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2018 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER 001-36159 STEREOTAXIS, INC. (Exact name of the Registrant as Specified in its Charter) DELAWARE 94-3120386 (State or Other Jurisdicti ...

Stereotaxis, Inc. (NYSE:STXS) Q4 2018 Earnings Conference Call March 12, 2019 10:00 AM ET Company Representatives David Fischel - Chairman, Chief Executive Officer Marty Stammer - Chief Financial Officer Conference Call Participants Chris Vaster - Private Investor Operator Good morning. Thank you for joining us for the Stereotaxis Fourth Quarter and Full Year 2018 Earnings Conference Call. Certain statements during the conference call and question-and-answer session to follow may relate to future events, ex ...

Investor Presentation 4Q 2018 2 Stereotaxis at a Glance Global Leader in Endovascular Robotics Focused on the Treatment of Cardiac Arrhythmias Extensive Presence 300+ Physicians | 100+ Active Systems | 31 Countries . Validated & Protected 100,000+ Procedures | 300+ Publications | 100+ Issued Patents. Attractive Market $4B+ Existing Market | 10-15% Annual Growth | No Robotic Competitor Financial Highlights* >$30m Sales | >80% Recurring Revenue | >75% Gross Margin . $12.0m Cash and No Debt Enterprise Value ~$ ...